Director/PDMR Shareholding

RNS Number : 8464U

Proteome Sciences PLC

27 October 2017

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Director/PDMR Shareholding

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 24 October 2017 and 25 October 2017, it purchased 75,000 and 109,460 ordinary shares of 1p each, respectively, in the capital of the Company ("Ordinary Shares") at an average price of 3.18p per Ordinary Share (the "Purchase"). Following the Purchase, Vulpes has a total direct and indirect interest in 55,197,431 equivalent to 18.69% of Proteome Sciences' total issued share capital.

The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 55,197,431 Ordinary Shares of the Company representing 18.69% of the issued share capital of the Company.

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Vulpes Life Sciences Fund
2.	Reason for the Notification
a)	Position/status	PCA of Martin Diggle (NED)
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Proteome Sciences plc
b)	LEI	213800Q62ICXANKU2986
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary Shares of 1p each
	Identification code	GB0003104196
b)	Nature of the transaction	Purchase of shares
c)	Price(s) and volume(s)	75,000 Ordinary Shares at 3.11p per Ordinary Share 109,460 Ordinary Shares at 3.25p per Ordinary Share
d)	Aggregated information: ·      Aggregated volume ·      Price	184,460 Ordinary Shares of 1p each purchased at an average price of 3.18p per Ordinary Share
e)	Date of the transaction	24, 25 October 2017
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

For further information:  Proteome Sciences plc
Jeremy Haigh, Chief Executive Officer                       Tel: [phone]
Ian Pike, Chief Scientific Officer
Stefan Fuhrman, Interim Finance Director
finnCap Limited (Nominated Adviser/Broker)
Geoff Nash/James Thompson	Tel: [phone]
Tony Quirke (broking)  IFC Advisory (Financial PR and IR)
Tim Metcalfe/Graham Herring/Miles Nolan	Tel: [phone]

 Notes for editors:

 About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant^®) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator^™). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services^™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

 

END

 

 

DSHFESFSWFWSEES